Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

BACKGROUND: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), is effective for the treatment of advanced non-small cell lung cancer (NSCLC). However, severe adverse events (AEs) have been reported in NSCLC patients treated with bevacizumab. C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Dis
Main Authors: Li, Li-Juan, Chen, Di-Fei, Wu, Guo-Feng, Guan, Wei-Jie, Zhu, Zheng, Liu, Yi-Qian, Gao, Guo-Ying, Qin, Yin-Yin, Zhong, Nan-Shan
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129907/
https://ncbi.nlm.nih.gov/pubmed/30233875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.07.09
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados